Tesamorelin vs Ipamorelin
Two growth hormone axis peptides acting at different receptors: a GHRH analogue studied with visceral adipose endpoints and a selective ghrelin-receptor agonist, compared by mechanism, molecular profile, and published combined-pathway studies.
Overview
Tesamorelin and Ipamorelin are frequently discussed side by side in growth hormone (GH) axis research because both act at pituitary receptors involved in GH regulation rather than being GH itself. They sit on different sides of the regulatory system, however. Tesamorelin is a stabilised analogue of growth hormone-releasing hormone (GHRH), the hypothalamic factor that tells the pituitary to release GH. Ipamorelin is a synthetic pentapeptide that acts on a separate receptor, the ghrelin/growth hormone secretagogue receptor (GHS-R), placing it in the secretagogue class alongside the GHRPs from which it was derived.
Tesamorelin is the more clinically characterised of the two: it is the GHRH analogue studied in large randomised trials that used visceral adipose tissue (VAT) as the measured endpoint in HIV-associated lipodystrophy. Ipamorelin is best known in the literature as the first GHS-R agonist reported to show GH-release selectivity comparable to GHRH in animal and cell models, without the ACTH and cortisol changes measured with earlier secretagogues. Understanding where these two mechanisms diverge, and how they have been examined together in combined-pathway studies, is what makes the comparison useful for designing GH-axis laboratory studies.
At a Glance
| Tesamorelin | Ipamorelin | |
|---|---|---|
| Class | GHRH (GRF 1-44) analogue | GH secretagogue (ghrelin/GHS-R agonist) |
| Receptor target | GHRH receptor (GHRH-R) | Ghrelin/GH secretagogue receptor (GHS-R1a) |
| Size | 44 amino acids (~5,136 g/mol) | 5 amino acids (~712 g/mol) |
| Primary mechanism studied | GHRH-receptor binding and cAMP signalling | Ghrelin-receptor (GHS-R1a) binding and calcium signalling |
| Most-cited research focus | Visceral adipose and hepatic endpoints in trials | GH-release selectivity in animal and cell models |
| Notable property | VAT measured as primary endpoint in randomised trials | Selectivity reported well above the ED50 in animal models |
Tesamorelin in Brief
Tesamorelin (developmental designation TH9507) is a synthetic analogue of human growth hormone-releasing hormone. It comprises the full 44-amino-acid sequence of GHRH (GRF 1-44) with an added trans-3-hexenoic acid group at the N-terminus, a modification reported to slow enzymatic degradation and extend stability relative to native GHRH. Because it works at the GHRH receptor on the pituitary, it is studied as a ligand that acts within the feedback-regulated GHRH pathway rather than bypassing it.
In research terms, Tesamorelin is most strongly associated with metabolic endpoints. The pivotal randomised, double-blind, placebo-controlled trials measured visceral adipose tissue by CT in patients with HIV-associated abdominal fat accumulation, with later work extending to liver fat (Falutz et al., 2007; Stanley et al., 2014). This positions it within the metabolic research cluster as well as the GH-axis cluster.
Ipamorelin in Brief
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) derived from growth hormone-releasing peptide-1 (GHRP-1). It acts as a selective agonist of the ghrelin/growth hormone secretagogue receptor (GHS-R1a), a distinct pathway from GHRH. The foundational characterisation described it as the first GHS-R agonist whose selectivity for GH release approached that of GHRH itself: in that animal work, ACTH and cortisol levels were not significantly different from GHRH stimulation, even at levels more than 200-fold above the ED50 for GH release (Raun et al., 1998).
That selectivity is the property most cited in Ipamorelin literature and is the reason it is grouped with GHRH analogues and other secretagogues in growth hormone research, including combined-pathway studies with GHRH-receptor ligands.
Mechanism of Action: Tesamorelin
Findings below are drawn from published research on Tesamorelin and on GHRH-receptor signalling:
- GHRH-receptor binding: Tesamorelin binds the pituitary GHRH receptor, the same target as endogenous GHRH, a Gs-coupled receptor that signals through the cAMP second-messenger pathway.
- Stabilised structure:The N-terminal trans-3-hexenoic acid modification is reported to reduce susceptibility to dipeptidyl peptidase degradation, extending the molecule's functional residence time relative to native GRF 1-44.
- Downstream IGF-1: Published trials measured insulin-like growth factor 1 (IGF-1) as a secondary marker of GH-axis activity; see the cited sources for reported values.
- Visceral adipose endpoint: In randomised trials the primary measured endpoint was visceral adipose tissue by CT (Falutz et al., 2007; Stanley et al., 2014); see the cited sources for reported results.
Mechanism of Action: Ipamorelin
Findings below are drawn from published in-vitro and animal-model research on Ipamorelin and the ghrelin receptor:
- Ghrelin-receptor binding: Ipamorelin is a GHS-R1a ligand; in rat pituitary cell preparations it was characterised through intracellular calcium signalling, a pathway distinct from GHRH signalling (Raun et al., 1998).
- Selectivity in animal models: In the characterising animal study its GH-release potency was comparable to GHRP-6, without the significant ACTH and cortisol changes measured with GHRP-6 and GHRP-2, which is why it is described as a selective secretagogue.
- Distinct from GHRH analogues:Because GHRPs and GHRH act through separate receptors, Ipamorelin's mechanism is distinct from, not redundant with, a GHRH analogue such as Tesamorelin.
- GHRP-1 lineage: Ipamorelin was identified by modifying GHRP-1, a design step reported to preserve GH-releasing potency while improving receptor selectivity.
Combined-Pathway Studies
GHRH-receptor and ghrelin-receptor ligands act on two different pituitary receptors via two different second-messenger systems, GHRH through cAMP and secretagogues through intracellular calcium. Because the pathways are separate, published physiology research has examined how the two signalling systems interact in the control of pulsatile GH secretion (Norman et al., 2013).
In a laboratory setting, this is why the two classes are compared side by side: Tesamorelin is a GHRH-receptor ligand and Ipamorelin is a selective ghrelin-receptor ligand, so together they cover both receptor arms in combined-pathway studies. Other GHRH analogues have also been examined alongside Ipamorelin in the published literature. All framing here is mechanistic and drawn from published research; it is not a recommendation for any use outside the laboratory.
Molecular Profiles
| Tesamorelin | Ipamorelin | |
|---|---|---|
| Molecular formula | C221H366N72O67S | C38H49N9O5 |
| Molecular weight | ~5,135.9 g/mol | ~711.9 g/mol |
| Sequence length | 44 amino acids (GRF 1-44 + trans-3-hexenoic acid) | 5 amino acids (Aib-His-D-2-Nal-D-Phe-Lys-NH2) |
| CAS number | 218949-48-5 | 170851-70-4 |
| PubChem CID | 16137828 | 9831659 |
| Half-life (reported) | Short; minutes-range in circulation | Short; approximately 2 hours reported |
| Form | Lyophilised powder | Lyophilised powder |
| Purity | ≥98% (HPLC) | ≥98% (HPLC) |
Key Mechanistic Differences
The two peptides are studied in the GH axis but act at different receptors and have different research footprints:
- Receptor and pathway: Tesamorelin acts at the GHRH receptor via cAMP; Ipamorelin acts at the ghrelin receptor (GHS-R1a) via intracellular calcium.
- Size and structure: Tesamorelin is a large 44-residue GHRH analogue; Ipamorelin is a compact synthetic pentapeptide.
- Research footprint: Tesamorelin is the more clinically studied compound, with randomised trials measuring visceral adipose and hepatic endpoints; Ipamorelin is characterised primarily in animal and cell pharmacology studies.
- Selectivity emphasis:Ipamorelin's defining literature point is GH-release selectivity relative to ACTH/cortisol in animal models; Tesamorelin's is its use of visceral adipose tissue as a trial endpoint.
Key Published Research
Metabolic effects of a growth hormone-releasing factor in patients with HIV
Falutz J, et al. New England Journal of Medicine. 2007; 357(23):2359-2370 (PMID 18057338)
Randomised, double-blind, placebo-controlled trial of tesamorelin (the GHRH analogue) in patients with HIV and abdominal fat accumulation, with visceral adipose tissue by CT as the primary measured endpoint.
Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial
Stanley TL, et al. JAMA. 2014; 312(4):380-389 (PMID 25038357)
Extends the tesamorelin VAT work to include hepatic fat as a measured endpoint; see source for reported results.
Ipamorelin, the first selective growth hormone secretagogue
Raun K, et al. European Journal of Endocrinology. 1998; 139(5):552-561 (PMID 9849822)
Foundational in-vitro and animal characterisation of ipamorelin as a selective GHS-R agonist, including ACTH and cortisol measurements relative to the ED50 for GH release.
Differential pulsatile secretagogue control of GH secretion in healthy men
Norman C, et al. American Journal of Physiology - Regulatory, Integrative and Comparative Physiology. 2013; 304(9):R712-R719 (PMID 23485864)
Examines GHRH and secretagogue (GHRP-2) control of pulsatile GH secretion, examining how GHRH-receptor and ghrelin-receptor signalling interact; see source for findings.
Storage and Handling
Lyophilised (unreconstituted):Store at -20°C for long-term stability. Keep sealed and protected from light and moisture. Applies to both peptides.
Reconstituted:Store at 2-8°C and use within roughly 30 days. Avoid repeated freeze-thaw cycles.
Recommended solvent: Bacteriostatic water or sterile water for laboratory use.
Frequently Asked Questions
What is the main difference between Tesamorelin and Ipamorelin?
Tesamorelin is a 44-amino-acid GHRH (GRF 1-44) analogue that acts on the GHRH receptor, while Ipamorelin is a five-amino-acid secretagogue that acts on the separate ghrelin/GH secretagogue receptor. Both are studied in the GH axis, but through different receptors and second-messenger pathways.
Why is Tesamorelin associated with visceral adipose endpoints in research?
Its pivotal randomised trials used the change in visceral adipose tissue measured by CT as the primary endpoint in patients with HIV-associated fat accumulation, with later work extending to liver fat (Falutz et al., 2007; Stanley et al., 2014). That is why it is the GH-axis peptide most cited alongside visceral adipose endpoints.
Why are a GHRH analogue and a secretagogue compared?
Because they act on different pituitary receptors through different second-messenger pathways, published physiology research has examined how the two signalling systems interact (Norman et al., 2013). That is the basis for combined-pathway studies of the two classes.
Is Tesamorelin or Ipamorelin better?
Neither is universally "better". They are studied for different mechanisms and endpoints, so the appropriate choice depends entirely on the research question being investigated.
What purity should they be for research?
Both should be ≥98% purity as verified by HPLC, with a certificate of analysis available to confirm purity and identity.
Researchers comparing related GHRH analogues may also reference the Sermorelin product page and the Ipamorelin vs Sermorelin comparison.
Disclaimer: This information is compiled from published peer-reviewed literature and is provided for educational and research reference purposes only. It does not constitute medical advice. The peptides referenced here, sold by Enhanced Research Compounds, are intended exclusively for in-vitro research and laboratory use. They are not therapeutic goods, are not listed on the ARTG, and are not approved for human or animal consumption.